EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF(V600E) mutation: a case report and review of literature

Despite the promising initial anti-tumor efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), most advanced non-small-cell lung cancers (NSCLCs) progress eventually due to therapeutic resistance. V-Raf murine sarcoma viral oncogene homolog B1 (BRAF)(V600E) mutation ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Ran, Luo, Lifeng, Sun, Xianwen, Bao, Zhiyao, Du, Wei, Dai, Ranran, Tang, Wei, Gao, Beili, Xiang, Yi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992450/
https://www.ncbi.nlm.nih.gov/pubmed/35582379
http://dx.doi.org/10.20517/cdr.2021.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992450/
https://www.ncbi.nlm.nih.gov/pubmed/35582379
http://dx.doi.org/10.20517/cdr.2021.98

Ejemplares similares